Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside DOI Open Access
Mohammad Almasri, Nawar Maher, Bashar Al Deeban

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(10), С. 4869 - 4869

Опубликована: Май 19, 2025

Liquid biopsy through the analysis of circulating tumor DNA (ctDNA) is emerging as a powerful and non-invasive tool complementing tissue in lymphoma management. Whilst remains diagnostic gold standard, it fails to detect molecular heterogeneity tumor’s multiple compartments poses challenges for sequential disease monitoring. In diffuse large-B-cell (DLBCL), ctDNA facilitates genotyping by identifying hallmark mutations (e.g., MYD88, CD79B, EZH2), enabling cluster classification. Dynamic changes levels during DLBCL treatment correlate strongly with progression-free survival overall survival, underscoring its value predictive prognostic biomarker. Hodgkin’s lymphoma, characterized scarcity malignant cells biopsies, provides reliable insights into biology, response therapy, relapse risk. primary central nervous system detection MYD88 L265P offers highly sensitive, specific, minimally invasive option. Likewise, aggressive T-cell lymphomas, supports profiling, aligns burden, shows high concordance tissue-based results. Ongoing future clinical trials will be critical validating standardizing applications, ultimately integrating liquid routine practice more personalized dynamic care.

Язык: Английский

Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies DOI Open Access
Nawar Maher, Samir Mouhssine, Bassam Francis Matti

и другие.

Cancers, Год журнала: 2025, Номер 17(5), С. 907 - 907

Опубликована: Март 6, 2025

Histological transformation (HT) into aggressive lymphoma is a turning point in significant fraction of patients affected by indolent lymphoproliferative neoplasms, namely, chronic lymphocytic leukemia (CLL), follicular (FL), marginal zone lymphomas (MZLs), and lymphoplasmacytic (LPL) [...]

Язык: Английский

Процитировано

1
Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside DOI Open Access
Mohammad Almasri, Nawar Maher, Bashar Al Deeban

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(10), С. 4869 - 4869

Опубликована: Май 19, 2025

Liquid biopsy through the analysis of circulating tumor DNA (ctDNA) is emerging as a powerful and non-invasive tool complementing tissue in lymphoma management. Whilst remains diagnostic gold standard, it fails to detect molecular heterogeneity tumor’s multiple compartments poses challenges for sequential disease monitoring. In diffuse large-B-cell (DLBCL), ctDNA facilitates genotyping by identifying hallmark mutations (e.g., MYD88, CD79B, EZH2), enabling cluster classification. Dynamic changes levels during DLBCL treatment correlate strongly with progression-free survival overall survival, underscoring its value predictive prognostic biomarker. Hodgkin’s lymphoma, characterized scarcity malignant cells biopsies, provides reliable insights into biology, response therapy, relapse risk. primary central nervous system detection MYD88 L265P offers highly sensitive, specific, minimally invasive option. Likewise, aggressive T-cell lymphomas, supports profiling, aligns burden, shows high concordance tissue-based results. Ongoing future clinical trials will be critical validating standardizing applications, ultimately integrating liquid routine practice more personalized dynamic care.

Язык: Английский

Процитировано

0